Table 1.
SSc-related complications and comorbidities in inpatient population in the 2003–2017 period: number of cases and percentages by sex, referred to the inpatient population and test to assess statistically significant sex differences
| Cases | % | pr-test | ||
|---|---|---|---|---|
| Heart and Circulationa | M | 55 | 45.5 | 0.26 |
| F | 312 | 40.1 | ||
| Total | 367 | 40.8 | ||
| Acute myocardial infarction | M | 5 | 4.1 | 0.18 |
| F | 16 | 2.1 | ||
| Total | 21 | 2.3 | ||
| Subarachnoid and intracerebral haemorrhage | M | 1 | 0.8 | 0.83 |
| F | 8 | 1.0 | ||
| Total | 9 | 1.0 | ||
| Ischemic stroke events | M | 2 | 1.7 | 0.72 |
| F | 10 | 1.3 | ||
| Total | 12 | 1.3 | ||
| Congestive heart failure | M | 16 | 13.2 | 0.46 |
| F | 85 | 10.9 | ||
| Total | 101 | 11.2 | ||
| Malignant essential hypertension | M | 0 | 0.0 | 0.23 |
| F | 9 | 1.2 | ||
| Total | 9 | 1.0 | ||
| Gangrene | M | 2 | 1.7 | 0.48 |
| F | 22 | 2.8 | ||
| Total | 24 | 2.7 | ||
| Chronic ulcer of skin (except pressure ulcer) | M | 28 | 23.1 | 0.42 |
| F | 155 | 19.9 | ||
| Total | 183 | 20.4 | ||
| Lungb | M | 53 | 43.8 | 0.06 |
| F | 272 | 35.0 | ||
| Total | 325 | 36.2 | ||
| PAH | M | 5 | 4.1 | 0.33 |
| F | 50 | 6.4 | ||
| Total | 55 | 6.1 | ||
| Lung involvement | M | 38 | 31.4 | 0.39 |
| F | 215 | 27.6 | ||
| Total | 253 | 28.1 | ||
| Pulmonary fibrosis | M | 10 | 8.3 | 0.04 |
| F | 31 | 4.0 | ||
| Total | 41 | 4.6 | ||
| Pneumonia | M | 16 | 13.2 | 0.002 |
| F | 44 | 5.7 | ||
| Total | 60 | 6.7 | ||
| Pulmonary embolism | M | 0 | 0.0 | – |
| F | 13 | 1.7 | ||
| Total | 13 | 1.4 | ||
| Kidneyc | M | 5 | 4.1 | 0.91 |
| F | 34 | 4.4 | ||
| Total | 39 | 4.3 | ||
| Chronic kidney disease | M | 1 | 0.83 | 0.48 |
| F | 13 | 1.67 | ||
| Total | 14 | 1.56 | ||
| Acute renal failure | M | 4 | 3.3 | 0.95 |
| F | 25 | 3.2 | ||
| Total | 29 | 3.2 | ||
| Gastrointestinal tractd | M | 5 | 4.1 | 0.56 |
| F | 24 | 3.1 | ||
| Total | 29 | 3.2 | ||
| Hemorrhage of gastrointestinal tract | M | 0 | 0.0 | – |
| F | 4 | 0.5 | ||
| Total | 4 | 0.4 | ||
| Intestinal obstruction (without hernia) | M | 5 | 4.1 | 0.39 |
| F | 21 | 2.7 | ||
| Total | 26 | 2.9 | ||
| Metabolisme | M | 43 | 35.5 | 0.0001 |
| F | 153 | 19.7 | ||
| Total | 196 | 21.8 | ||
| Diabetes mellitus | M | 19 | 15.7 | 0.04 |
| F | 75 | 9.6 | ||
| Total | 94 | 10.5 | ||
| Gout | M | 32 | 26.4 | 0.0001 |
| F | 98 | 12.6 | ||
| Total | 130 | 14.5 | ||
| Malignant neoplasms | M | 18 | 14.9 | 0.55 |
| F | 100 | 12.9 | ||
| Total | 118 | 13.1 |
%, percentages referred to the total of the inpatient population; pr-test, p-value of the test of difference of proportion, a p-value < 0.05 (in bold) indicates a statistically significant difference in SSc-related complications between males and females
aCases with at least one occurrence of the following complications or comorbidities: acute myocardial infarction, subarachnoid and intracerebral haemorrhage, ischemic stroke events, congestive heart failure, malignant essential hypertension, gangrene, and chronic ulcer of skin
bCases with at least one occurrence of the following complications or comorbidities: PAH, lung involvement in systemic sclerosis, pneumonia, and pulmonary embolism
cCases with at least one occurrence of the following complications or comorbidities: chronic kidney disease and acute renal failure
dCases with at least one occurrence of the following complications or comorbidities: haemorrhage of gastrointestinal tract and intestinal obstruction
eCases with at least one occurrence of the following complications or comorbidities: diabetes mellitus and gout